Abstract
According to some researchs, Crohn’s disease (CD) and Ulcerative colitis (UC), two chronic inflammatory bowel illnesses, may be protected against Helicobacter pylori infection. Many case–control studies have revealed that individuals with CD and UC had lower H. pylori prevalence than healthy controls. However, whether or not H. pylori plays a protective role in the development of Crohn’s disease is debatable. CD was more common in H. pylori-negative individuals than in H. pylori-positive patients. After eradication of H. pylori, the CD was more common in the H. pylori-negative group than in the H. pylori-positive group over the previous research follow-up period. Although it has been strongly indicated in previous studies that H. pylori infection plays a significant role and triggers autoimmune reactions and may be implicated in the pathogenesis of autoimmune diseases, the role of H. pylori in inflammatory bowel disease, including Crohn’s disease, is unclear.
Keywords
- Helicobacter pylori
- Crohn’s disease
- immune cells
- cytokines
- Cronh’s Disease and H. pylori correlation
1. Introduction
Crohn’s disease (CD) is an inflammatory disease that could cause chronic inflammation throughout the gastrointestinal tract without a definite etiology [1]. Even though the incidence of CD has been increasing for several decades worldwide, it is more common in northern Europe and the United States compared to other areas, including southern Europe [2]. In addition to the primary contributor to the disease, which is the genetic predisposition, there is a growing body of evidence to support the concept that environmental variables, in particular the gut flora and antigens, are also involved in the development of Crohn’s disease (CD). Several different infections have been proposed as potential causes of CD without solid evidence supporting these hypotheses. There is an unmet need to investigate the role of bacteria during CD development. Helicobacter pylori (
2. Epidemiological correlation between CD and H. pylori
Author | Pooled RR/OR | 95% CI | p-Value |
---|---|---|---|
Yue et al. [21] | 0.63 | 0.49–0.81 | < 0.001 |
Luther et al. [22] | 0.6 | 0.40–0.72 | NR |
Wu et al. [10] | 0.43 | 0.37–0.50 | < 0.001 |
Wang et al. [23] | 0.41 | 0.32–0.53 | < 0.001 |
Hesamaddin et al. [24] | 0.40 | 0.33–0.49 | < 0.001 |
Rokkas et al. [19] | 0.38 | 0.31–0.47 | < 0.001 |
Castañorodríguez et al. [25] | 0.38 | 0.31–0.47 | < 0.001 |
Ding et al. [26] | 0.236 | 0.14–0.39 | < 0.001 |
Table 1.
A number of hypotheses have been proposed to explain this discovery. For instance, if patients with Crohn’s disease received antibiotics prior to an
Various researches included the ecological epidemiology studies in order to tackle the issue of overcoming biases and confounding in their researches. Information regarding the prevalence and incidence of CD was combined with geographically and temporally matched studies of the prevalence of
3. Molecular mechanisms
A few different immunological mechanisms that are responsible for the possible negative correlation between
Probiotics may be useful to reduce intestinal inflammation if they are administered to reestablish a healthy balance in the microbiota of the gut and/or to reset the immunological systems that have been dysregulated [19]. The anti-inflammatory and immune-modulatory effects of probiotics help decrease inflammation by inhibiting the production of pro-inflammatory cytokines and enhancing the production of anti-inflammatory cytokines. This is how probiotics work to reduce inflammation. There have been conflicting reports on using probiotics in terms of efficacy as part of a therapeutic strategy to eradicate
The toxic strains of
The elimination of
Putting aside any and all objections, the current research is a significant evidence that lends credence to the idea that the occurrences of
Recent research results suggest that the processes that are responsible for the association may be more convoluted than previously thought. This is due to the fact that variables other than
4. Conclusion
Researchers have concluded that
References
- 1.
Wang TC. Yamada’s Textbook of Gastroenterology. Hoboken, NJ: Wiley; 2022 p. 1 online resource - 2.
Sylla P, Kaiser AM, Popowich D. The SAGES Manual of Colorectal Surgery. Cham: Springer; 2020 p. 1 online resource - 3.
Tersigni R, Prantera C. Crohn’s Disease: A Multidisciplinary Approach. Dordrecht: Springer; 2010 xviii, p. 303 - 4.
Buratovich MA. Principles of Microbiology. Principles of Science. Amenia, NY, USA: Salem Press, a division of EBSCO Information Services; 2022 xxix, 697 pages - 5.
Guandalini S, Dhawan A. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition: A Comprehensive Guide to Practice. Cham: Springer; 2022 p. 1 online resource - 6.
Shiotani A. Gastric cancer: With Special Focus on Studies from Japan. Singapore: Springer; 2019 p. viii, 201 pages - 7.
Kamiya S, Backert S. Helicobacter pylori in Human Diseases, in Advances in Microbiology, Infectious Diseases and Public Health. Cham, Switzerland: Springer; 2019 p. xix, 284 pages - 8.
Chichlowski M, Hale LP. Effects of Helicobacter infection on research: The case for eradication of Helicobacter from rodent research colonies. Comparative Medicine. 2009; 59 (1):10-17 - 9.
Yu Y et al. Helicobacter pylori infection and inflammatory bowel disease: A crosstalk between upper and lower digestive tract. Cell Death & Disease. 2018;9 (10):961 - 10.
Wu XW et al. Helicobacter pylori infection and inflammatory bowel disease in Asians: A meta-analysis. World Journal of Gastroenterology. 2015;21 (15):4750-4756 - 11.
Papamichael K, Konstantopoulos P, Mantzaris GJ. Helicobacter pylori infection and inflammatory bowel disease: Is there a link? World Journal of Gastroenterology. 2014;20 (21):6374-6385 - 12.
Sun J. Inflammation, Infection, and Microbiome in Cancers: Evidence, Mechanisms, and Implications, in Physiology in Health and Disease. Cham, Switzerland: Springer; 2021 p. xii, 509 pages - 13.
Kanoun O, Derbel N. Advanced Sensors for Biomedical Applications, in Smart Sensors, Measurement and Instrumentation. Cham: Springer; 2021 p. 1 online resource - 14.
Nordenfelt P, Otto MW. Bacterial Pathogenesis: Methods and Protocols, in Springer Protocols. New York: Humana Press: Springer; 2017 p. xi, 357 pages - 15.
Gracia-sancho J, Salvadó MJ. Gastrointestinal Tissue: Oxidative Stress and Dietary Antioxidants. London: Academic Press; 2017 xvii, 376 pages - 16.
Suzuki H, Warren JR, Marshall BJ. Helicobacter pylori . Japan: Springer; 2016 p. x, 267 pages - 17.
Lanas A. NSAIDs and Aspirin: Recent Advances and Implications for Clinical Management. Switzerland: Springer; 2016 p. 1 online resource - 18.
Wang WL, Xu XJ. Correlation between Helicobacter pylori infection and Crohn's disease: A meta-analysis. European Review for Medical and Pharmacological Sciences. 2019; 23 (23):10509-10516 - 19.
Rokkas T et al. The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis. United European Gastroenterology Journal. 2015;3 (6):539-550 - 20.
Jones K. Cancer sourcebook: Basic consumer health information about major forms and stages of cancer, featuring facts about head and neck cancers, lung cancers, gastrointestinal cancers, genitourinary cancers, lymphomas, blood cell cancers, endocrine cancers, skin cancers, bone cancers, metastatic cancers, and more; along with facts about cancer treatments, cancer risks and prevention. In: Health Reference Series. Detroit, MI, USA: Omnigraphics; p. 2015 77 entries - 21.
Yue M et al. Is Helicobacter pylori infection associated with celiac disease? A Meta-analysis. The Turkish Journal of Gastroenterology. 2022;33 (3):205-212 - 22.
Luther J et al. Association between Helicobacter pylori infection and inflammatory bowel disease: A meta-analysis and systematic review of the literature. Inflammatory Bowel Diseases. 2010;16 (6):1077-1084 - 23.
Wang WL, Xu XJ. Correlation between Helicobacter pylori infection and Crohn’s disease: A meta-analysis. European Review for Medical and Pharmacological Sciences. Dec 2019;23 (23):10509-10516. DOI: 10.26355/eurrev_201912_19691. PMID: 31841206 - 24.
Shirzad-Aski H et al. Association between Helicobacter pylori colonization and inflammatory bowel disease: A systematic review and Meta-analysis. Journal of Clinical Gastroenterology. 2021;55 (5):380-392 - 25.
Castano-Rodriguez N et al. Dual role of Helicobacter and Campylobacter species in IBD: A systematic review and meta-analysis. Gut. 2017; 66 (2):235-249 - 26.
Ding ZH et al. The prevalence of Helicobacter pylori infection in inflammatory bowel disease in China: A case-control study. PLoS One. 2021;16 (3):e0248427 - 27.
Chun HJ et al. Small Intestine Disease: A Comprehensive Guide to Diagnosis and Management. Singapore: Springer; 2022. p. 1 online resource - 28.
Hohenberger W, Parker M. Lower Gastrointestinal Tract Surgery. Vol. 2, Open Procedures, in Springer Surgery Atlas Series. Cham: Springer; 2021 p. xvii, 614 pages - 29.
Hyman N, Fleshner P, Strong S. Mastery of IBD Surgery. Cham: Springer; 2019 p. xi, 409 pages, color illustrations - 30.
Kohlstadt I. Food and Nutrients in Disease Management. Boca Raton: CRC Press; 2009 xxii, 717 pages - 31.
Wyllie R, Hyams JS, Kay M. Pediatric Gastrointestinal and Liver Disease. Sixth edition ed. Philadelphia, PA: Elsevier; 2021 xx, 1091 pages - 32.
Zhong Y et al. The relationship between Helicobacter pylori and inflammatory bowel disease. Archives of Iranian Medicine. 2021;24 (4):317-325 - 33.
Bartels LE et al. Diagnosis of Helicobacter pylori infection is associated with lower prevalence and subsequent incidence of Crohn's disease. Journal of Crohn's & Colitis. 2016;10 (4):443-448 - 34.
Engstrand L, Graham DY. Microbiome and gastric Cancer. Digestive Diseases and Sciences. 2020; 65 (3):865-873 - 35.
Bartels LE, Dahlerup JF. Association of Helicobacter pylori and Crohn’s disease incidence: An inversion reaction? Digestive Diseases and Sciences. 2017;62 (9):2217-2219 - 36.
Xiang Z et al. Helicobacter pylori and Crohn's disease: A retrospective single-center study from China. World Journal of Gastroenterology. 2013;19 (28):4576-4581 - 37.
Roka K et al. The prevalence of Helicobacter pylori gastritis in newly diagnosed children with inflammatory bowel disease. Helicobacter. 2014;19 (5):400-405 - 38.
Lender N et al. Review article: Associations between Helicobacter pylori and obesity--an ecological study. Alimentary Pharmacology & Therapeutics. 2014;40 (1):24-31 - 39.
Toscano EP et al. Epidemiological and clinical-pathological aspects of Helicobacter pylori infection in Brazilian children and adults. Gastroenterology Research and Practice. 2018;2018 :8454125 - 40.
Shah A et al. Is there a link between H. pylori and the epidemiology of Crohn’s disease? Digestive Diseases and Sciences. 2017;62 (9):2472-2480 - 41.
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nature Reviews. Gastroenterology & Hepatology. 2015; 12 (4):205-217 - 42.
Singh S et al. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nature Reviews. Gastroenterology & Hepatology. 2015; 12 (1):26-35 - 43.
Luther J et al. Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis. Gut. 2011;60 (11):1479-1486 - 44.
Owyang SY et al. Helicobacter pylori DNA’s anti-inflammatory effect on experimental colitis. Gut Microbes. 2012;3 (2):168-171 - 45.
Kim JM et al. Helicobacter pylori vacuolating cytotoxin induces apoptosis via activation of endoplasmic reticulum stress in dendritic cells. Journal of Gastroenterology and Hepatology. 2015;30 (1):99-108 - 46.
Dixon BREA, Hossain R, Patel RV, Algood HMS. Th17 cells in Helicobacter pylori infection: A dichotomy of help and harm. Infection and Immunity. 18 Oct 2019;87 (11):e00363-19. DOI: 10.1128/IAI.00363-19. PMID: 31427446; PMCID: PMC6803329 - 47.
Bhuiyan TR et al. Th1 and Th17 responses to Helicobacter pylori in Bangladeshi infants, children and adults. PLoS One. 2014;9 (4):e93943 - 48.
Ansari S, Yamaoka Y. Animal models and Helicobacter pylori infection. Journal of Clinical Medicine. 31 May 2022;11 (11):3141. DOI: 10.3390/jcm11113141. PMID: 35683528; PMCID: PMC9181647 - 49.
Vital JS, Tanoeiro L, Lopes-Oliveira R, Vale FF. Biomarker characterization and prediction of virulence and antibiotic resistance from Helicobacter pylori next generation sequencing data. Biomolecules. 11 May 2022;12 (5):691. DOI: 10.3390/biom12050691. PMID: 35625618; PMCID: PMC9138241 - 50.
Suzuki R et al. Genome-wide mutation analysis of Helicobacter pylori after inoculation to Mongolian gerbils. Gut Pathog. 2019; 11 :45 - 51.
Cooper TK et al. Research-relevant conditions and pathology of laboratory mice, rats, gerbils, Guinea pigs, hamsters, naked mole rats, and rabbits. ILAR Journal. 2021; 62 (1-2):77-132 - 52.
Israel DA et al. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. The Journal of Clinical Investigation. 2001;107 (5):611-620 - 53.
Oster P et al. The efficacy of Cancer immunotherapies is compromised by Helicobacter pylori infection. Frontiers in Immunology. 2022;13 :899161 - 54.
Reyes VE, Peniche AG. Helicobacter pylori deregulates T and B cell Signaling to trigger immune evasion. Current Topics in Microbiology and Immunology. 2019;421 :229-265 - 55.
Baj J, Forma A, Sitarz M, Portincasa P, Garruti G, Krasowska D, et al. Helicobacter pylori virulence factors-mechanisms of bacterial pathogenicity in the gastric microenvironment. Cells. 25 Dec 2020;10 (1):27. DOI: 10.3390/cells10010027. PMID: 33375694; PMCID: PMC7824444 - 56.
Gravina AG et al. Helicobacter pylori and extragastric diseases: A review. World Journal of Gastroenterology. 2018;24 (29):3204-3221 - 57.
Wang L et al. Helicobacter pylori and autoimmune diseases: Involving multiple systems. Frontiers in Immunology. 2022;13 :833424 - 58.
Bravo D et al. Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects. World Journal of Gastroenterology. 2018;24 (28):3071-3089 - 59.
Arnold IC, Muller A. Helicobacter pylori : Does gastritis prevent colitis? Inflamm Intest Dis. 2016;1 (3):102-112 - 60.
Fujita Y et al. Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer. BMC Gastroenterology. 2021;21 (1):424 - 61.
Axelrad JE et al. The role of gastrointestinal pathogens in inflammatory bowel disease: A systematic review. Therapeutic Advances in Gastroenterology. 2021; 14 :17562848211004493 - 62.
Sultan S et al. Metabolic influences of gut microbiota Dysbiosis on inflammatory bowel disease. Frontiers in Physiology. 2021; 12 :715506 - 63.
Raoul P, Cintoni M, Palombaro M, Basso L, Rinninella E, Gasbarrini A, et al. Food additives, a key environmental factor in the development of IBD through gut Dysbiosis. Microorganisms. 13 Jan 2022; 10 (1):167. DOI: 10.3390/microorganisms10010167. PMID: 35056616; PMCID: PMC8780106 - 64.
Zhang L et al. Bacterial species associated with human inflammatory bowel disease and their pathogenic mechanisms. Frontiers in Microbiology. 2022; 13 :801892 - 65.
Dann SM et al. Giardia infection of the small intestine induces chronic colitis in genetically susceptible hosts. Journal of Immunology. 2018; 201 (2):548-559 - 66.
Van Der Kraak LA et al. Genetic and commensal induction of IL-18 drive intestinal epithelial MHCII via IFNgamma. Mucosal Immunology. 2021; 14 (5):1100-1112 - 67.
Choi MS et al. Helicobacter pylori -derived outer membrane vesicles stimulate interleukin 8 secretion through nuclear factor kappa B activation. The Korean Journal of Internal Medicine. 2021;36 (4):854-867 - 68.
Uotani T et al. Changes of tight junction and interleukin-8 expression using a human gastroid monolayer model of Helicobacter pylori infection. Helicobacter. 2019;24 (3):e12583 - 69.
Alexander SM et al. Helicobacter pylori in human stomach: The inconsistencies in clinical outcomes and the probable causes. Frontiers in Microbiology. 2021;12 :713955 - 70.
Mladenova I. Clinical relevance of Helicobacter pylori infection. Journal of Clinical Medicine. 2021;10 :3473. DOI: 10.3390/jcm10163473 - 71.
Taylor JM et al. Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microbial Pathogenesis. 2008;44 (1):20-27 - 72.
Lindenberg M et al. Clarithromycin impairs tissue-resident memory and Th17 responses to macrolide-resistant Streptococcus pneumoniae infections. Journal of Molecular Medicine (Berlin, Germany). 2021;99 (6):817-829 - 73.
Liu J et al. Erythromycin suppresses the cigarette smoke extract-exposed dendritic cell-mediated polarization of CD4(+) T cells into Th17 cells. Journal of Immunology Research. 2020; 2020 :1387952 - 74.
Takemori N et al. Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma. Ecancermedicalscience. 2020; 14 :1088 - 75.
Liu W et al. Mechanism of TH2/TH17-predominant and neutrophilic TH2/TH17-low subtypes of asthma. The Journal of Allergy and Clinical Immunology. 2017; 139 (5):1548-1558 e4 - 76.
Kim JJE et al. Efficacy of clarithromycin depends on the bacterial density in clarithromycin-Heteroresistant Helicobacter pylori infections: An In situ detected susceptibility and quantitative morphometry-based retrospective study. Pathology Oncology Research. 2021;27 :1609863 - 77.
Mishima K et al. Lansoprazole upregulates Polyubiquitination of the TNF receptor-associated factor 6 and facilitates Runx2-mediated Osteoblastogenesis. eBioMedicine. 2015; 2 (12):2046-2061